Safety is the most important question when considering any new medication. And when it comes to GLP-1 receptor agonists like semaglutide, it's one of the most thoroughly studied questions in modern medicine.
Here's what the research actually shows about the safety of GLP-1 weight loss medications.
A Medication Studied on a Massive Scale
GLP-1 receptor agonists have been studied in tens of thousands of patients:
FDA Approval History
Each approval was based on comprehensive safety and efficacy data reviewed by the FDA.
What the Research Shows About Safety
### Common Side Effects (Mild and Temporary)
The most common side effects are digestive and generally mild:
These are most common during the first weeks and with each dose increase. They typically improve over time.
### Serious Side Effects (Rare)
Serious adverse events are uncommon:
### The SELECT Trial: Key Safety Data
The SELECT trial (17,604 patients, 40-month follow-up) found:
Serious adverse events occurred in 33.4% of the semaglutide group vs. 36.4% of the placebo group, meaning semaglutide patients actually had fewer serious events.
Who Should NOT Take GLP-1 Medications
Contraindications include:
Building Trust Through Transparency
At Majesta Health, we believe in being completely transparent about both the benefits and risks of GLP-1 treatment. Every patient consultation includes a thorough review of your medical history to identify any potential risks. We don't prescribe medication to everyone, and we never will.
The Bottom Line
Based on the totality of clinical evidence, GLP-1 medications have a well-established safety profile when used under proper medical supervision. The most common side effects are mild and temporary. Serious adverse events are rare.
The key to safe use: 1. Proper medical screening before starting 2. Gradual dose escalation 3. Regular monitoring by a healthcare provider 4. Open communication about any side effects
Ready to learn more? Start your 2-minute medical assessment to discuss your options with a board-certified physician.
Related guides
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider. Individual results may vary. Safety data referenced from STEP and SELECT trials published in The New England Journal of Medicine.
Frequently Asked Questions
Is semaglutide safe for long-term use?
Semaglutide has been studied in long-term trials including STEP-5, which followed patients for 104 weeks (2 years), and SELECT, which followed 17,604 adults with cardiovascular disease for an average of 39.8 months on semaglutide 2.4 mg. The safety profile remained consistent over time, with no new categories of side effects emerging during extended use. SELECT also showed a 20% reduction in major adverse cardiovascular events on semaglutide vs placebo, suggesting net long-term benefit in the studied population. Long-term safety in patients without cardiovascular risk factors is still being characterized.
Has the FDA approved semaglutide as safe?
Yes. The FDA approved semaglutide as Ozempic for type 2 diabetes in 2017, as Rybelsus (oral) in 2019, and as Wegovy for chronic weight management in 2021. FDA approval requires that the benefits outweigh the risks for the labeled use. Brand-name semaglutide carries a boxed warning regarding thyroid C-cell tumors based on rodent studies, with human relevance unknown. Compounded semaglutide uses the same FDA-registered active pharmaceutical ingredient but is prepared as an individualized prescription by a state-licensed compounding pharmacy. Compounded medications are not FDA-approved as final products.
What are the safety risks of semaglutide?
Documented risks include gastrointestinal side effects (nausea, vomiting, diarrhea, constipation), pancreatitis, gallbladder disease, hypoglycemia in patients also taking insulin or sulfonylureas, kidney injury (most often secondary to dehydration), diabetic retinopathy complications in patients with existing retinopathy, and the boxed warning about thyroid C-cell tumors. Pregnancy and planned pregnancy in the near term are contraindications. Patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take semaglutide.
Is compounded semaglutide safe?
Safety on compounded semaglutide depends on three things: a US-licensed physician prescribing within the labeled dose range with appropriate contraindication screening, a state-licensed compounding pharmacy that follows USP 795 and 797 sterile compounding standards, and ongoing patient monitoring through the treatment course. Compounded medications are not FDA-approved as final products, so the safety record is established through the FDA-registered active pharmaceutical ingredient plus the pharmacy compliance framework rather than through brand-name finished-drug clinical trials. Patients should verify their telehealth provider uses pharmacies with NABP accreditation and LegitScript certification.
Who should not take semaglutide?
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior episodes of pancreatitis, severe gastroparesis, and pregnancy or planned pregnancy in the near term. Patients with severe kidney disease, severe gallbladder disease, or active diabetic retinopathy should discuss the risk-benefit balance with their physician before starting. Patients who are breastfeeding should also avoid semaglutide based on current labeling. A licensed physician makes the final eligibility determination based on full medical history.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner, MD Integrations (MDI). Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through the MD Integrations Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)